EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications

Reina Ito iD, Hiroyuki Suzuki iD, Kenichiro Ishikawa, Kazutake Yagi, Akira Ohkoshi iD, Yukio Katori, Mika K Kaneko iD, Yukinari Kato iD

Antibodies · 10.07.2026 · 15 (4) · 59

DOI: 10.3390/antib15040059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibodies, online erschienen am 10.07.2026. Verfasst von Reina Ito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Cadherin-17 (CDH17, LI-cadherin) is a non-classical cadherin with an atypical structure and unique functions. CDH17 expression is restricted to normal intestinal epithelium. Furthermore, CDH17 functions as an oncoprotein that promotes tumor migration and invasion in colorectal, gastric, and pancreatic cancers. Therefore, CDH17 is an important diagnostic marker and therapeutic target. The CDH17-directed strategies, including monoclonal antibodies (mAbs), bispecific Abs, antibody–drug conjugates (ADCs), and chimeric antigen receptor (CAR) T cells, have been evaluated in preclinical and clinical studies. Therefore, developing mAbs that specifically recognize cell surface-expressing CDH17 is essential for advancing both tumor diagnosis and therapy.

Methods

Anti-human CDH17 mAbs (named Ca17Mabs) were developed by immunizing a mouse with CDH17-overexpressed cells and a high-throughput screening using flow cytometry.

Results

Among Ca17Mabs, a clone, Ca17Mab-5 (IgG1, κ) specifically recognized CDH17-overexpressed Chinese hamster ovary-K1 (CHO/CDH17) cells with no detectable cross-reactivity to 21 other CDHs by flow cytometry. Ca17Mab-5 also detected endogenous CDH17 in human colorectal cancer cell lines, COLO201 and COLO205. The apparent dissociation constant (KD) values of Ca17Mab-5 for CHO/CDH17 and COLO205 were estimated as 1.5 × 10−8 M and 1.3 × 10−8 M, respectively. Furthermore, Ca17Mab-5 detected endogenous CDH17 by Western blotting. In immunohistochemistry, Ca17Mab-5 exhibited clear membranous staining in normal colon epithelium, colorectal, gastric, and pancreatic cancers.

Conclusions

Ca17Mab-5 is a versatile tool for detecting CDH17 and has potential for tumor diagnosis.

Schlagwörter

Stichwörter der Autor:innen

CDH17Cadherin-17Cell-Based Immunization and Screeningflow cytometryimmunohistochemistrymonoclonal antibody

Autor:innen und Institutionen

  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.

ORCID-Profile: Reina Ito, Hiroyuki Suzuki, Akira Ohkoshi, Mika K Kaneko, Yukinari Kato

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Ito, R., Suzuki, H., Ishikawa, K., Yagi, K., Ohkoshi, A., Katori, Y., Kaneko, M. K., & Kato, Y. (2026). A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications. Antibodies, 15(4), 59. https://doi.org/10.3390/antib15040059

Vancouver

Ito R, Suzuki H, Ishikawa K, Yagi K, Ohkoshi A, Katori Y, et al. A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications. Antibodies. 2026;15(4):59. doi:10.3390/antib15040059

BibTeX
@article{Ito2026,
  author = {Ito, Reina and Suzuki, Hiroyuki and Ishikawa, Kenichiro and Yagi, Kazutake and Ohkoshi, Akira and Katori, Yukio and Kaneko, Mika K and Kato, Yukinari},
  title = {A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {59},
  doi = {10.3390/antib15040059}
}
Kostenlos starten →